Drug pricing deadlock stalls hundreds of new medicines, strands investment
Hundreds of new medicines remain stuck without pricing approval, leaving patients waiting while companies see investments frozen
Hundreds of new medicines remain stuck without pricing approval, leaving patients waiting while companies see investments frozen